tetano
Editor, Senior Moderator
Med J Aust
. 2021 Feb 3.
doi: 10.5694/mja2.50940. Online ahead of print.
Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020
Heather F Gidding[SUP] 1 2 3 [/SUP], Dorothy A Machalek[SUP] 4 [/SUP], Alexandra J Hendry[SUP] 1 [/SUP], Helen E Quinn[SUP] 1 5 [/SUP], Kaitlyn Vette[SUP] 1 [/SUP], Frank H Beard[SUP] 1 5 [/SUP], Hannah S Shilling[SUP] 6 [/SUP], Rena Hirani[SUP] 7 [/SUP], Iain B Gosbell[SUP] 7 8 [/SUP], David O Irving[SUP] 7 9 [/SUP], Linda Hueston[SUP] 10 [/SUP], Marnie Downes[SUP] 11 [/SUP], John B Carlin[SUP] 11 12 [/SUP], Matthew Vn O'Sullivan[SUP] 10 13 14 [/SUP], Dominic E Dwyer[SUP] 10 13 14 [/SUP], John M Kaldor[SUP] 4 [/SUP], Kristine Macartney[SUP] 1 5 [/SUP]
Affiliations
Abstract
Objectives: To estimate SARS-CoV-2-specific antibody seroprevalence after the first epidemic wave of coronavirus disease 2019 (COVID-19) in Sydney.
Setting, participants: People of any age who had provided blood for testing at selected diagnostic pathology services (general pathology); pregnant women aged 20-39 years who had received routine antenatal screening; and Australian Red Cross Lifeblood plasmapheresis donors aged 20-69 years.
Design: Cross-sectional study; testing of de-identified residual blood specimens collected during 20 April - 2 June 2020.
Main outcome measure: Estimated proportions of people seropositive for anti-SARS-CoV-2-specific IgG, adjusted for test sensitivity and specificity.
Results: Thirty-eight of 5339 specimens were IgG-positive (general pathology, 19 of 3231; antenatal screening, 7 of 560; plasmapheresis donors, 12 of 1548); there were no clear patterns by age group, sex, or location of residence. Adjusted estimated seroprevalence among people who had had general pathology blood tests (all ages) was 0.15% (95% credible interval [CrI], 0.04-0.41%), and 0.29% (95% CrI, 0.04-0.75%) for plasmapheresis donors (20-69 years). Among 20-39-year-old people, the age group common to all three collection groups, adjusted estimated seroprevalence was 0.24% (95% CrI, 0.04-0.80%) for the general pathology group, 0.79% (95% CrI, 0.04-1.88%) for the antenatal screening group, and 0.69% (95% CrI, 0.04-1.59%) for plasmapheresis donors.
Conclusions: Estimated SARS-CoV-2 seroprevalence was below 1%, indicating that community transmission was low during the first COVID-19 epidemic wave in Sydney. These findings suggest that early control of the spread of COVID-19 was successful, but efforts to reduce further transmission remain important.
Keywords: COVID-19; Epidemiology; Infectious diseases; Respiratory tract infections.
. 2021 Feb 3.
doi: 10.5694/mja2.50940. Online ahead of print.
Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020
Heather F Gidding[SUP] 1 2 3 [/SUP], Dorothy A Machalek[SUP] 4 [/SUP], Alexandra J Hendry[SUP] 1 [/SUP], Helen E Quinn[SUP] 1 5 [/SUP], Kaitlyn Vette[SUP] 1 [/SUP], Frank H Beard[SUP] 1 5 [/SUP], Hannah S Shilling[SUP] 6 [/SUP], Rena Hirani[SUP] 7 [/SUP], Iain B Gosbell[SUP] 7 8 [/SUP], David O Irving[SUP] 7 9 [/SUP], Linda Hueston[SUP] 10 [/SUP], Marnie Downes[SUP] 11 [/SUP], John B Carlin[SUP] 11 12 [/SUP], Matthew Vn O'Sullivan[SUP] 10 13 14 [/SUP], Dominic E Dwyer[SUP] 10 13 14 [/SUP], John M Kaldor[SUP] 4 [/SUP], Kristine Macartney[SUP] 1 5 [/SUP]
Affiliations
- PMID: 33538019
- DOI: 10.5694/mja2.50940
Abstract
Objectives: To estimate SARS-CoV-2-specific antibody seroprevalence after the first epidemic wave of coronavirus disease 2019 (COVID-19) in Sydney.
Setting, participants: People of any age who had provided blood for testing at selected diagnostic pathology services (general pathology); pregnant women aged 20-39 years who had received routine antenatal screening; and Australian Red Cross Lifeblood plasmapheresis donors aged 20-69 years.
Design: Cross-sectional study; testing of de-identified residual blood specimens collected during 20 April - 2 June 2020.
Main outcome measure: Estimated proportions of people seropositive for anti-SARS-CoV-2-specific IgG, adjusted for test sensitivity and specificity.
Results: Thirty-eight of 5339 specimens were IgG-positive (general pathology, 19 of 3231; antenatal screening, 7 of 560; plasmapheresis donors, 12 of 1548); there were no clear patterns by age group, sex, or location of residence. Adjusted estimated seroprevalence among people who had had general pathology blood tests (all ages) was 0.15% (95% credible interval [CrI], 0.04-0.41%), and 0.29% (95% CrI, 0.04-0.75%) for plasmapheresis donors (20-69 years). Among 20-39-year-old people, the age group common to all three collection groups, adjusted estimated seroprevalence was 0.24% (95% CrI, 0.04-0.80%) for the general pathology group, 0.79% (95% CrI, 0.04-1.88%) for the antenatal screening group, and 0.69% (95% CrI, 0.04-1.59%) for plasmapheresis donors.
Conclusions: Estimated SARS-CoV-2 seroprevalence was below 1%, indicating that community transmission was low during the first COVID-19 epidemic wave in Sydney. These findings suggest that early control of the spread of COVID-19 was successful, but efforts to reduce further transmission remain important.
Keywords: COVID-19; Epidemiology; Infectious diseases; Respiratory tract infections.